Clinical Trials Logo

Iris Melanoma clinical trials

View clinical trials related to Iris Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02068586 Active, not recruiting - Iris Melanoma Clinical Trials

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Start date: November 19, 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.

NCT ID: NCT01143402 Active, not recruiting - Iris Melanoma Clinical Trials

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Start date: June 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective than selumetinib in treating melanoma of the eye.